Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847650 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT02847650 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 57 participants.
The verdict
NCT02847650, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
Interventions
- DRUG Placebo
- DRUG PF-06649751
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2018-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02847650
The ClinicalTrials.gov registry entry for NCT02847650 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02847650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02847650 about?
NCT02847650 is a clinical study titled "Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease". The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
What is the current status of trial NCT02847650?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2016-10-17. Estimated completion is 2018-01-29.
What interventions are being tested in trial NCT02847650?
The interventions under investigation include: Placebo (DRUG), PF-06649751 (DRUG).
Who is sponsoring clinical trial NCT02847650?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.